Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 6Colorectal Neoplasms 3Brain Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Stomach Neoplasms 1Metastatic Breast Cancer With a Isolated Brain Progression 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1HER2-positive Breast Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1Anatomic Stage IA Breast Cancer AJCC v8 1Adenocarcinoma Of Esophagus 1

Interventions

Sunitinib 2tucatinib 1testosterone 17 beta-cypionate 1pembrolizumab 1dodecyl maltoside 1cabozantinib 1Urinary Diversion 1Trastuzumab 1Testosterone Propionate 1Standard of Care 1Saline Solution 1Radiosurgery 1Psychiatric Nursing 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Methyltestosterone 1Lidocaine 1Immune Checkpoint Inhibitors 1Fulvestrant 1Doxycycline 1Cystectomy 1Control Groups 1Ado-Trastuzumab Emtansine 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urologic Neoplasms × tucatinib × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡